Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.

Volume: 51, Issue: 4, Pages: 510 - 515
Published: Apr 1, 2019
Abstract
null null Background null Anti-TNF therapies infliximab (IFX), adalimumab (ADA), and golimumab (GOL) are approved for treating moderate to severe ulcerative colitis (UC). In UC, only the switch from IFX to ADA has been investigated, reaching no more than 10–43% remission rates at 12 months. null null null Aim null Of the present study was to investigate disease outcome after a switch from subcutaneous (SC) agents to the intravenous (IV) agent...
Paper Details
Title
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
Published Date
Apr 1, 2019
Volume
51
Issue
4
Pages
510 - 515
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.